{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:17:42Z","timestamp":1793830662560,"version":"4.6.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274260"],"award-info":[{"award-number":["82274260"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The co-occurrence of chronic hepatitis B (CHB) and metabolic dysfunction-associated fatty liver disease (MAFLD) has drawn considerable attention due to its impact on disease outcomes. This study aimed to investigate the association between hepatic steatosis and hepatitis B virus (HBV) and analyzed the influence of hepatic steatosis on hepatitis B virology in patients with CHB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this cross-sectional study, 272 patients infected with HBV who were treatment-na\u00efve or had ceased antiviral treatment for\u2009&gt;\u20096\u00a0months were categorized into the CHB group (n\u2009=\u2009128) and CHB\u2009+\u2009MAFLD group (n\u2009=\u2009144). Furthermore, based on whether HBV DNA was higher than 2000\u00a0IU\/mL, patients were categorized into the high-level HBV DNA group (n\u2009=\u2009129) and the low-level HBV DNA group (n\u2009=\u2009143). The impact of hepatic steatosis on hepatitis B virology was analyzed within the CHB cohort. Multivariate logistic regression analysis was employed to identify independent factors influencing pre-genomic RNA (pgRNA) levels below the lower limit of detection (LLD) in patients with CHB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 272 patients, compared with CHB group, HBV DNA levels (4.11 vs. 3.62 log\n                      <jats:sub>10<\/jats:sub>\n                      IU\/mL,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.045), hepatitis B surface antigen (HBsAg) levels (3.52 vs. 3.20 log\n                      <jats:sub>10<\/jats:sub>\n                      IU\/mL,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.008) and the hepatitis B e antigen (HBeAg) positive rate (33.6% vs. 22.2%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.036) were significantly decreased in the CHB\u2009+\u2009MAFLD group; In 143 low-level HBV DNA patients, the CHB\u2009+\u2009MAFLD group exhibited decreased levels of pgRNA and HBsAg compared to the CHB group. However, in 129 high-level HBV DNA patients, a more significant decrease was observed in pgRNA (3.85 vs 3.35 log\n                      <jats:sub>10<\/jats:sub>\n                      copies\/mL,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.044) and HBsAg (3.85 vs 3.59 log\n                      <jats:sub>10<\/jats:sub>\n                      IU\/mL,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.033); Spearman correlation analysis revealed a negative correlation between hepatic steatosis and pgRNA (r\u2009=\u2009\u2009\u2212\u20090.529,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), HBV DNA (r\u2009=\u2009\u2009\u2212\u20090.456,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), HBsAg (r\u2009=\u2009\u2009\u2212\u20090.465,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) and HBeAg (r\u2009=\u2009\u2009\u2212\u20090.339,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) levels; Multivariate logistic regression analysis identified HBV DNA (odds ratio [OR]\u2009=\u20090.283,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), HBsAg (OR\u2009=\u20090.300,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), and controlled attenuation parameter (CAP) values (OR\u2009=\u20091.013,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.038) as independent factors influencing pgRNA levels below the LLD in patients with CHB.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study establishes a negative correlation between hepatic steatosis and hepatitis B virology, demonstrating decreased HBV expression in patients with CHB\u2009+\u2009MAFLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12985-023-02277-8","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T09:02:19Z","timestamp":1705654939000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Correlation analysis of hepatic steatosis and hepatitis B virus: a cross-sectional study"],"prefix":"10.1186","volume":"21","author":[{"given":"Sitong","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghui","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwei","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"issue":"3","key":"2277_CR1","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/liv.14369","volume":"40","author":"J Zhang","year":"2020","unstructured":"Zhang J, Lin S, Jiang D, et al. Chronic hepatitis B and non-alcoholic fatty liver disease: Conspirators or competitors? Liver Int. 2020;40(3):496\u2013508.","journal-title":"Liver Int"},{"issue":"9","key":"2277_CR2","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1111\/liv.15252","volume":"42","author":"M Yang","year":"2022","unstructured":"Yang M, Wei L. Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia. Liver Int. 2022;42(9):1981\u201390.","journal-title":"Liver Int"},{"issue":"5","key":"2277_CR3","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s12072-018-9877-7","volume":"12","author":"D Hu","year":"2018","unstructured":"Hu D, Wang H, Wang H, et al. Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model. Hepatol Int. 2018;12(5):438\u201346.","journal-title":"Hepatol Int"},{"key":"2277_CR4","doi-asserted-by":"publisher","first-page":"965548","DOI":"10.3389\/fimmu.2022.965548","volume":"13","author":"E Tourkochristou","year":"2022","unstructured":"Tourkochristou E, Assimakopoulos SF, Thomopoulos K, Marangos M, Triantos C. NAFLD and HBV interplay-related mechanisms underlying liver disease progression. Front Immunol. 2022;13:965548.","journal-title":"Front Immunol"},{"issue":"4","key":"2277_CR5","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s11684-017-0590-z","volume":"11","author":"F Lu","year":"2017","unstructured":"Lu F, Wang J, Chen X, Xu D, Xia N. Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs. Front Med. 2017;11(4):502\u20138.","journal-title":"Front Med"},{"issue":"1","key":"2277_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u20139.","journal-title":"J Hepatol"},{"issue":"5","key":"2277_CR7","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","volume":"66","author":"T Karlas","year":"2017","unstructured":"Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022\u201330.","journal-title":"J Hepatol"},{"issue":"26","key":"2277_CR8","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.3748\/wjg.v27.i26.3971","volume":"27","author":"YW Shi","year":"2021","unstructured":"Shi YW, Yang RX, Fan JG. Chronic hepatitis B infection with concomitant hepatic steatosis: current evidence and opinion. World J Gastroenterol. 2021;27(26):3971\u201383.","journal-title":"World J Gastroenterol"},{"issue":"9","key":"2277_CR9","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/j.1440-1746.2011.06801.x","volume":"26","author":"MV Machado","year":"2011","unstructured":"Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol. 2011;26(9):1361\u20137.","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"2277_CR10","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jhep.2011.09.013","volume":"56","author":"VW Wong","year":"2012","unstructured":"Wong VW, Wong GL, Chu WC, et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol. 2012;56(3):533\u201340.","journal-title":"J Hepatol"},{"issue":"4","key":"2277_CR11","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jhep.2020.05.040","volume":"73","author":"LY Mak","year":"2020","unstructured":"Mak LY, Hui RW, Fung J, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol. 2020;73(4):800\u20136.","journal-title":"J Hepatol"},{"issue":"10","key":"2277_CR12","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1007\/s10620-014-3180-9","volume":"59","author":"MM Wang","year":"2014","unstructured":"Wang MM, Wang GS, Shen F, Chen GY, Pan Q, Fan JG. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors. Dig Dis Sci. 2014;59(10):2571\u20139.","journal-title":"Dig Dis Sci"},{"issue":"5","key":"2277_CR13","doi-asserted-by":"publisher","first-page":"e27909","DOI":"10.5812\/hepatmon.15(5)2015.27909","volume":"15","author":"RN Zhang","year":"2015","unstructured":"Zhang RN, Pan Q, Zhang Z, Cao HX, Shen F, Fan JG. Saturated Fatty Acid inhibits viral replication in chronic hepatitis B virus infection with nonalcoholic Fatty liver disease by toll-like receptor 4-mediated innate immune response. Hepat Mon. 2015;15(5):e27909.","journal-title":"Hepat Mon"},{"key":"2277_CR14","doi-asserted-by":"publisher","first-page":"106507","DOI":"10.1016\/j.phrs.2022.106507","volume":"185","author":"S Khanmohammadi","year":"2022","unstructured":"Khanmohammadi S, Kuchay MS. Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease. Pharmacol Res. 2022;185:106507.","journal-title":"Pharmacol Res"},{"issue":"10","key":"2277_CR15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1042\/CS20110065","volume":"121","author":"R Broering","year":"2011","unstructured":"Broering R, Lu M, Schlaak JF. Role of Toll-like receptors in liver health and disease. Clin Sci (Lond). 2011;121(10):415\u201326.","journal-title":"Clin Sci (Lond)"},{"key":"2277_CR16","doi-asserted-by":"publisher","first-page":"S259","DOI":"10.1016\/S0168-8278(22)00890-X","volume":"77","author":"N Patel","year":"2022","unstructured":"Patel N, Boghici D, Rava M, et al. Enhanced T cell responses in patients and mouse model of hepatitis B and comorbid non-alcoholic fatty liver disease. J Hepatol. 2022;77:S259\u201360.","journal-title":"J Hepatol"},{"issue":"1","key":"2277_CR17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.bbrc.2011.10.013","volume":"415","author":"Y Mao","year":"2011","unstructured":"Mao Y, Da L, Tang H, et al. Hepatitis B virus X protein reduces starvation-induced cell death through activation of autophagy and inhibition of mitochondrial apoptotic pathway. Biochem Biophys Res Commun. 2011;415(1):68\u201374.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"2277_CR18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0016-5085(03)00907-7","volume":"125","author":"AE Feldstein","year":"2003","unstructured":"Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 2003;125(2):437\u201343.","journal-title":"Gastroenterology"},{"issue":"3","key":"2277_CR19","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/hep.24809","volume":"55","author":"S Wang","year":"2012","unstructured":"Wang S, Qiu L, Yan X, et al. Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G(1)-modulated P53 activity. Hepatology. 2012;55(3):730\u201341.","journal-title":"Hepatology"},{"issue":"1","key":"2277_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s10020-019-0085-2","volume":"25","author":"JK Long","year":"2019","unstructured":"Long JK, Dai W, Zheng YW, Zhao SP. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1\/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease. Mol Med. 2019;25(1):26.","journal-title":"Mol Med"},{"issue":"43","key":"2277_CR21","doi-asserted-by":"publisher","first-page":"16003","DOI":"10.1073\/pnas.0607837103","volume":"103","author":"A Shlomai","year":"2006","unstructured":"Shlomai A, Paran N, Shaul Y. PGC-1alpha controls hepatitis B virus through nutritional signals. Proc Natl Acad Sci U S A. 2006;103(43):16003\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2277_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12944-021-01461-5","volume":"20","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Chen D, Gong Q, et al. Elucidation of SIRT-1\/PGC-1\u03b1-associated mitochondrial dysfunction and autophagy in nonalcoholic fatty liver disease. Lipids Health Dis. 2021;20(1):40.","journal-title":"Lipids Health Dis"},{"issue":"2","key":"2277_CR23","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.virol.2010.10.024","volume":"409","author":"S Yoon","year":"2011","unstructured":"Yoon S, Jung J, Kim T, et al. Adiponectin, a downstream target gene of peroxisome proliferator-activated receptor \u03b3, controls hepatitis B virus replication. Virology. 2011;409(2):290\u20138.","journal-title":"Virology"},{"issue":"3","key":"2277_CR24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.metabol.2010.09.003","volume":"60","author":"SA Polyzos","year":"2011","unstructured":"Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism. 2011;60(3):313\u201326.","journal-title":"Metabolism"},{"key":"2277_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/1743-422X-7-228","volume":"7","author":"A Mohamadkhani","year":"2010","unstructured":"Mohamadkhani A, Sayemiri K, Ghanbari R, Elahi E, Poustchi H, Montazeri G. The inverse association of serum HBV DNA level with HDL and adiponectin in chronic hepatitis B infection. Virol J. 2010;7:228.","journal-title":"Virol J"},{"issue":"1","key":"2277_CR26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261\u201383.","journal-title":"Hepatology"},{"issue":"4","key":"2277_CR27","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jhep.2016.05.029","volume":"65","author":"J Wang","year":"2016","unstructured":"Wang J, Shen T, Huang X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol. 2016;65(4):700\u201310.","journal-title":"J Hepatol"},{"issue":"2","key":"2277_CR28","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jhep.2016.09.028","volume":"66","author":"K Giersch","year":"2017","unstructured":"Giersch K, Allweiss L, Volz T, Dandri M, L\u00fctgehetmann M. Serum HBV pgRNA as a clinical marker for cccDNA activity. J Hepatol. 2017;66(2):460\u20132.","journal-title":"J Hepatol"},{"issue":"6","key":"2277_CR29","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3390\/v13060951","volume":"13","author":"A Vachon","year":"2021","unstructured":"Vachon A, Osiowy C. Novel biomarkers of hepatitis B virus and their use in chronic hepatitis B patient management. Viruses. 2021;13(6):951.","journal-title":"Viruses"},{"issue":"2","key":"2277_CR30","first-page":"104","volume":"45","author":"G Roncarati","year":"2022","unstructured":"Roncarati G, Galli S, Ferniani T, Moroni A, Lazzarotto T. Evaluation of pregenomic HBV RNA in HBeAg-negative patients. New Microbiol. 2022;45(2):104\u201310.","journal-title":"New Microbiol"},{"issue":"4","key":"2277_CR31","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","volume":"61","author":"Q Ning","year":"2014","unstructured":"Ning Q, Han M, Sun Y, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol. 2014;61(4):777\u201384.","journal-title":"J Hepatol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-023-02277-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-023-02277-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-023-02277-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T09:03:32Z","timestamp":1705655012000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-023-02277-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2277"],"URL":"https:\/\/doi.org\/10.1186\/s12985-023-02277-8","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]},"assertion":[{"value":"2 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A statement of Helsinki was used in this study and was approved by the Ethics Committee of the First Affiliated Hospital of Dalian Medical University (No. PJ-KS-KY-2022-291) and Clinical trial registration (ChiCTR2200063555). Informed consent was obtained from all subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}